These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 10699539

  • 1. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.
    Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S.
    J Pain Symptom Manage; 2000 Feb; 19(2):118-29. PubMed ID: 10699539
    [Abstract] [Full Text] [Related]

  • 2. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
    Pai V, Porter K, Ranalli M.
    Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
    [Abstract] [Full Text] [Related]

  • 3. [Management of chemotherapy induced diarrhea].
    Schultz M, Schölmerich J, Kullmann F.
    Z Gastroenterol; 2004 Jun; 42(6):527-38. PubMed ID: 15190449
    [Abstract] [Full Text] [Related]

  • 4. Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
    Wadler S, Benson AB, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E.
    J Clin Oncol; 1998 Sep; 16(9):3169-78. PubMed ID: 9738589
    [Abstract] [Full Text] [Related]

  • 5. Octreotide in the management of treatment-related diarrhoea.
    Baillie-Johnson HR.
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():11-5. PubMed ID: 8822080
    [Abstract] [Full Text] [Related]

  • 6. Octreotide in the management of diarrhea induced by graft versus host disease.
    Ippoliti C, Neumann J.
    Oncol Nurs Forum; 1998 Jun; 25(5):873-8. PubMed ID: 9644703
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy induced diarrhea.
    Richardson G, Dobish R.
    J Oncol Pharm Pract; 2007 Dec; 13(4):181-98. PubMed ID: 18045778
    [Abstract] [Full Text] [Related]

  • 8. The assessment and management of cancer treatment-related diarrhea.
    O'Brien BE, Kaklamani VG, Benson AB.
    Clin Colorectal Cancer; 2005 Mar; 4(6):375-81; discussion 382-3. PubMed ID: 15807929
    [Abstract] [Full Text] [Related]

  • 9. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.
    Ippoliti C, Champlin R, Bugazia N, Przepiorka D, Neumann J, Giralt S, Khouri I, Gajewski J.
    J Clin Oncol; 1997 Nov; 15(11):3350-4. PubMed ID: 9363865
    [Abstract] [Full Text] [Related]

  • 10. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients.
    Ippoliti C.
    Am J Health Syst Pharm; 1998 Aug 01; 55(15):1573-80. PubMed ID: 9706182
    [Abstract] [Full Text] [Related]

  • 11. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation.
    Bianco JA, Higano C, Singer J, Appelbaum FR, McDonald GB.
    Transplantation; 1990 Jun 01; 49(6):1194-5. PubMed ID: 2360261
    [No Abstract] [Full Text] [Related]

  • 12. [Management of cancer treatment-related diarrhea and constipation].
    Tsuji Y, Sagawa T, Takayanagi N, Hirayama Y, Sakamaki S.
    Nihon Rinsho; 2003 Jun 01; 61(6):966-72. PubMed ID: 12806944
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation.
    Morton AJ, Durrant ST.
    Clin Transplant; 1995 Jun 01; 9(3 Pt 1):205-8. PubMed ID: 7549062
    [Abstract] [Full Text] [Related]

  • 14. Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child.
    Beckman RA, Siden R, Yanik GA, Levine JE.
    J Pediatr Hematol Oncol; 2000 Jun 01; 22(4):344-50. PubMed ID: 10959906
    [Abstract] [Full Text] [Related]

  • 15. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease.
    Ely P, Dunitz J, Rogosheske J, Weisdorf D.
    Am J Med; 1991 Jun 01; 90(6):707-10. PubMed ID: 2042686
    [Abstract] [Full Text] [Related]

  • 16. Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
    Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S.
    J Clin Oncol; 2004 Jul 15; 22(14):2918-26. PubMed ID: 15254061
    [Abstract] [Full Text] [Related]

  • 17. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
    Rosenoff S.
    Support Care Cancer; 2004 Aug 15; 12(8):561-70. PubMed ID: 15160318
    [Abstract] [Full Text] [Related]

  • 18. [Chemotherapy-induced diarrhea].
    Kobayashi K.
    Gan To Kagaku Ryoho; 2003 Jun 15; 30(6):765-71. PubMed ID: 12852342
    [Abstract] [Full Text] [Related]

  • 19. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
    Rosenoff SH, Gabrail NY, Conklin R, Hohneker JA, Berg WJ, Warsi G, Maloney J, Benedetto JJ, Miles EA, Zhu W, Anthony L.
    J Support Oncol; 2006 Jun 15; 4(6):289-94. PubMed ID: 16805331
    [Abstract] [Full Text] [Related]

  • 20. Constipation and diarrhea in patients with cancer.
    Solomon R, Cherny NI.
    Cancer J; 2006 Jun 15; 12(5):355-64. PubMed ID: 17034672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.